Fig. 1.

Study design. Using two different epigenome-wide technologies, 699 human tissue samples have been analyzed to identify a total of 31 regions whose methylation status has been analyzed in two serum sets consisting of 151 serum samples. Three markers have been validated in three independent settings: serum set 3, which consisted of 250 serum samples, from women with various benign and malignant conditions of the female genital tract. NACT set, consisting of serial samples from women with advanced stage ovarian cancer before and during chemotherapy. UKCTOCS (United Kingdom Collaborative Trial of Ovarian Cancer Screening) set which included serum samples from those 43 of the 101,539 women in the control arm who developed OC within 2 years; for each case, three control women who did not develop OC within 5 years of sample donation have been matched